InvestSMART

Pilbara Gold Limited (ASX: PGL) - Announcements

- Current share price for PGL : $0.485

ASX company news and announcements for Pilbara Gold Limited (PGL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Pilbara Gold Limited (PGL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Pilbara Gold Limited (PGL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Pilbara Gold Limited (PGL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$113 Trading Halt 9 Mar 2009 9:05AM $0.875 $0.485 fallen by 44.57%
$113 Half Yearly Report and Accounts 19 Feb 2009 4:05PM $0.820 $0.485 fallen by 40.85%
$113 Appendix 3C - Announcement of Buy-Back 5 Feb 2009 1:57PM $0.895 $0.485 fallen by 45.81%
$113 Progen and Avexa Merger Update 23 Jan 2009 1:52PM $0.870 $0.485 fallen by 44.25%
$113 Progen and Avexa to Merge 22 Dec 2008 10:23AM $0.760 $0.485 fallen by 36.18%
$113 Chairman`s Address to Shareholders 24 Nov 2008 10:52AM $0.800 $0.485 fallen by 39.38%
$113 Further details on capital return to shareholders 17 Nov 2008 5:37PM $0.640 $0.485 fallen by 24.22%
$113 Sale of PharmaSynth 17 Nov 2008 10:44AM $0.640 $0.485 fallen by 24.22%
$113 Letter to Shareholders on Strategy 13 Nov 2008 9:56AM $0.630 $0.485 fallen by 23.02%
$113 Request for Trading Halt and Trading Halt 11 Nov 2008 9:41AM n/a $0.485 n/a
$113 Nasdaq Deficiency Notice 8 Sep 2008 12:19PM $0.710 $0.485 fallen by 31.69%
$113 Progen Restructure 4 Sep 2008 11:06AM $0.675 $0.485 fallen by 28.15%
$113 Preliminary Final Report 28 Aug 2008 2:38PM $0.680 $0.485 fallen by 28.68%
$113 Progen Resumes Phase 1 Development of Anti-Cancer Agent 14 Aug 2008 4:42PM $0.680 $0.485 fallen by 28.68%
$113 Progen Terminates PATHWAY Trial 23 Jul 2008 9:33AM $0.580 $0.485 fallen by 16.38%
$113 Progen Spins-Out Manufacturing Business 2 Jul 2008 8:30AM $1.240 $0.485 fallen by 60.89%
$113 Presentation of data on Progen`s cancer epigenetic targets 30 May 2008 3:18PM $1.350 $0.485 fallen by 64.07%
$113 Progen Resumes Phase 1 Development of Anti-Cancer Agent 15 May 2008 10:53AM $1.380 $0.485 fallen by 64.86%
$113 Progen Restructures Manufacturing and Drug Discovery 27 Mar 2008 3:58PM $1.520 $0.485 fallen by 68.09%
$113 Commencement of Global Phase 3 Study for PI-88 11 Mar 2008 10:10AM $1.330 $0.485 fallen by 63.53%
$113 Half Yearly Report and Accounts 18 Feb 2008 11:30AM $1.385 $0.485 fallen by 64.98%
$113 Preliminary PI-88 Phase 2 Prostate Cancer Results 13 Feb 2008 4:04PM $1.730 $0.485 fallen by 71.97%
$113 Acquisition of Cellgate, Inc 4 Feb 2008 10:34AM $1.950 $0.485 fallen by 75.13%
$113 Financial Update 1 Feb 2008 11:50AM n/a $0.485 n/a
$113 Update on Phase 3 Clinical Program for PI-88 in Liver Cancer 21 Dec 2007 2:37PM $2.420 $0.485 fallen by 79.96%

501 - 525 of 575 results

Page 21 of 23

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.